Synlogic(US:SYBX)2021-08-12 13:30Clinical Program Updates - Synlogic expects clinical proof of concept data across multiple programs in 2021, including two opportunities in metabolic programs: Phenylketonuria (PKU) and Enteric Hyperoxaluria[8] - For Phenylketonuria (PKU), SYNB1618 Phase 2 SynPheny patient data and SYNB1934 Head to Head data with SYNB1618 in healthy volunteers are expected in the second half of 2021[9] - For Enteric Hyperoxaluria, SYNB8802 has demonstrated proof of mechanism in Phase 1A with dietary hyperoxaluria induced in healthy volunteers, and Phase 1B patient data is expected in the second half of 2021[9] - SYNB8802 at a dose of 3e11 live cells is advancing to Phase 1B in patients with Enteric Hyperoxaluria[37] - A Phase 2 SynPheny proof of concept read-out for SYNB1618 in PKU is expected in H2 2021[29, 51] - A Phase 1B proof of concept read-out for SYNB8802 in Enteric Hyperoxaluria is expected in H2 2021[29, 51] - In a Phase 1A study, SYNB8802 demonstrated a clinically meaningful lowering of urinary oxalate, with a 28.6% LS mean change over Placebo[39, 40] Financial Results - Synlogic reported cash, cash equivalents, and marketable securities of $115.5 million as of June 30, 2021, compared to $100.4 million as of December 31, 2020[45] - Research and Development (R&D) expenses for the three months ended June 30, 2021, were $10.7 million, compared to $12.9 million for the same period in 2020[46] - General and Administrative (G&A) expenses for the three months ended June 30, 2021, were $4.1 million, compared to $3.5 million for the same period in 2020[46] - Net loss for the three months ended June 30, 2021, was $14.5 million, or $0.28 per share, compared to a net loss of $15.5 million, or $0.44 per share, for the same period in 2020[46]